TNFSF13 antibody (Middle Region)
Quick Overview for TNFSF13 antibody (Middle Region) (ABIN926638)
Target
See all TNFSF13 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- Middle Region
-
Purification
- Purified
-
Immunogen
- TNFSF13 antibody was raised in rabbit using the middle region of TNFSF13 as the immunogen
-
-
-
-
Application Notes
- Optimal conditions should be determined by the investigator.
-
Comment
-
TNFSF13 Blocking Peptide, (ABIN938064), is also available for use as a blocking control in assays to test for specificity of this TNFSF13 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))
-
Alternative Name
- TNFSF13
-
Background
- The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF17/BCMA, a member of the TNF receptor family. This protein and its receptor are both found to be important for B cell development. In vitro experiments suggested that this protein may be able to induce apoptosis through its interaction with other TNF receptor family proteins such as TNFRSF6/FAS and TNFRSF14/HVEM. Alternative splicing results in multiple transcript variants. Some transcripts that skip the last exon of the upstream gene (TNFSF12) and continue into the second exon of this gene have been identified, such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13. Synonyms: Polyclonal TNFSF13 antibody, Anti-TNFSF13 antibody, tumor necrosis factor, ligand superfamily, member 13 antibody, APRIL antibody, CD256 antibody, TALL2 antibody, TRDL-1 antibody, UNQ383/PRO715 antibody, ligand antibody.
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response
Target
-